By contrast, a similar analysis in pancreatic cancer cell lines failed to detect changes in mitochondrial morphology in a cell line model with amplified OPA1, potentially because of the well-established impact of mutant KRAS on Drp1 activation (Supplementary Fig. 1c)3,4. The gene discussed is KRAS; the disease is pancreatic neoplasm.